« Return to News | Clinical Intelligence

Adeona's reaZin study meets primary outcomes

Friday, April 15, 2011 12:32 PM

Adeona Pharmaceuticals, a developer of medicines for CNS diseases, has results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The clinical study met the primary outcome of increasing serum zinc and decreasing serum free copper. In addition, secondary outcomes of mental status as measured by three standardized cognitive tests all favored the treatment group versus the placebo group.

The treatment group showed significant reductions in serum free copper levels and elevations in serum zinc levels over the placebo group, resulting in a highly statistically significant change in the free copper to zinc ratio (-20.8%), the primary outcome of the clinical study(p < 0.0006). An average net decrease in serum free copper of 6.5microg/dL for the treatment group versus placebo group, an average net increase in serum zinc of 64.6 microg/dL for the treatment group versus the placebo group was evident.

The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), showed an average net improvement of 0.41 points in favor of the treatment group versus placebo (p < 0.36. Clinical Dementia Rating Scale-Sum of Boxes (CDR-SOB), showed an average net improvement of 0.38 points in favor of the treatment group versus placebo (p < 0.10). Mini Mental State Examination (MMSE), showed an average net improvement of 0.19 points in favor of the treatment group versus placebo (p

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.